首页 › 公司 › THRX
Theseus Pharmaceuticals, Inc.（THRX）高管持股异动
该公司内部人(高管 / 董事 / 10% 以上股东)向 SEC 申报的交易记录。
完整申报记录(含历史)
本站从 SEC EDGAR 收录的历史 Form 4 申报(共 58 条)。此区为完整数据档案,与上方带中文解读的精选申报分开呈现。
| 申报日 | 申报人 | 表单 | 类型 | 金额 | 净股数 |
|---|---|---|---|---|---|
| 2024-02-14 | Kathy Yi | 4 | 回售予公司 | — | — |
| 2024-02-14 | Iain D. Dukes | 4 | 回售予公司 | — | -38.8 万股 |
| 2024-02-14 | Carl L Gordon | 4 | 回售予公司 | — | -1771.4 万股 |
| 2024-02-14 | Donald J Jr Hayden | 4 | 回售予公司 | — | -1.0 万股 |
| 2024-02-14 | Steven H Stein | 4 | 回售予公司 | — | — |
| 2024-02-14 | ORBIMED ADVISORS LLC | 4 | 要约收购处置 | — | -1771.4 万股 |
| 2024-02-14 | Bradford D. Dahms | 4 | 回售予公司 | — | -8,150 股 |
| 2023-11-07 | William Shakespeare | 4 | 期权行权取得 | $8.0 万 | 25.1 万股 |
| 2023-07-19 | ORBIMED ADVISORS LLC | 4 | 公开市场买入 | $146.4 万 | 48.0 万股 |
| 2023-07-19 | Carl L Gordon | 4 | 公开市场买入 | $146.4 万 | 48.0 万股 |
| 2023-07-19 | Foresite Capital Opportunity Management V, LLC | 4 | 公开市场买入 | $207.9 万 | 70.0 万股 |
| 2023-06-13 | Steven H Stein | 4 | 获授予/取得 | — | — |
| 2023-06-13 | Kathy Yi | 4 | 获授予/取得 | — | — |
| 2023-06-13 | Carl L Gordon | 4 | 获授予/取得 | — | — |
| 2023-06-13 | Iain D. Dukes | 4 | 获授予/取得 | — | — |
| 2023-06-13 | Donald J Jr Hayden | 4 | 获授予/取得 | — | — |
| 2023-03-02 | Victor Rivera | 4 | 获授予/取得 | — | — |
| 2023-03-02 | Bradford D. Dahms | 4 | 获授予/取得 | — | — |
| 2023-03-02 | William Shakespeare | 4 | 获授予/取得 | — | — |
| 2023-03-02 | Timothy P Clackson | 4 | 获授予/取得 | — | — |
| 2023-03-02 | David Kerstein | 4 | 获授予/取得 | — | — |
| 2023-02-21 | Bradford D. Dahms | 4 | 获授予/取得 | — | — |
| 2023-02-21 | Victor Rivera | 4 | 获授予/取得 | — | — |
| 2023-02-21 | David Kerstein | 4 | 获授予/取得 | — | — |
| 2023-02-21 | William Shakespeare | 4 | 获授予/取得 | — | — |
| 2023-02-21 | Timothy P Clackson | 4 | 获授予/取得 | — | — |
| 2023-01-03 | Foresite Capital Opportunity Management V, LLC | 4 | 公开市场买入 | $250.0 万 | 50.0 万股 |
| 2023-01-03 | Donald J Jr Hayden | 4 | 公开市场买入 | $5.0 万 | 1.0 万股 |
| 2022-12-01 | Bradford D. Dahms | 4 | 公开市场买入 | $1.0 万 | 1,502 股 |
| 2022-11-14 | Timothy P Clackson | 4 | 公开市场买入 | $1.7 万 | 2,500 股 |
| 2022-11-09 | Carl L Gordon | 4 | 公开市场买入 | $100.0 万 | 19.2 万股 |
| 2022-11-09 | OrbiMed Genesis GP LLC | 4 | 公开市场买入 | $100.0 万 | 19.2 万股 |
| 2022-10-19 | Steven H Stein | 4 | 获授予/取得 | — | — |
| 2022-06-13 | Iain D. Dukes | 4 | 获授予/取得 | — | — |
| 2022-06-13 | Carl L Gordon | 4 | 获授予/取得 | — | — |
| 2022-06-13 | Kathy Yi | 4 | 获授予/取得 | — | — |
| 2022-05-18 | Donald J Jr Hayden | 4 | 获授予/取得 | — | — |
| 2022-02-23 | William Shakespeare | 4 | 获授予/取得 | — | — |
| 2022-02-23 | David Kerstein | 4 | 获授予/取得 | — | — |
| 2022-02-23 | Timothy P Clackson | 4 | 获授予/取得 | — | — |
| 2022-02-23 | Bradford D. Dahms | 4 | 获授予/取得 | — | — |
| 2022-02-23 | David Dalgarno | 4 | 获授予/取得 | — | — |
| 2022-02-23 | Victor Rivera | 4 | 获授予/取得 | — | — |
| 2022-01-21 | OrbiMed Capital GP VII LLC | 4 | 公开市场买入 | $157.9 万 | 15.8 万股 |
| 2022-01-21 | Carl L Gordon | 4 | 公开市场买入 | $157.9 万 | 15.8 万股 |
| 2022-01-13 | OrbiMed Capital GP VII LLC | 4 | 公开市场买入 | $44.3 万 | 4.5 万股 |
| 2022-01-13 | Carl L Gordon | 4 | 公开市场买入 | $44.3 万 | 4.5 万股 |
| 2021-12-22 | Timothy P Clackson | 4 | 公开市场买入 | $2.5 万 | 2,600 股 |
| 2021-12-22 | Bradford D. Dahms | 4 | 公开市场买入 | $2.0 万 | 1,970 股 |
| 2021-10-15 | TAKEDA PHARMACEUTICAL CO LTD | 4 | 衍生证券转换 | — | 161.5 万股 |
| 2021-10-14 | William Shakespeare | 4 | 公开市场买入 | $1.0 万 | 625 股 |
| 2021-10-14 | Anne-mari Paster | 4 | 公开市场买入 | $300.0 万 | 71.1 万股 |
| 2021-10-14 | OrbiMed Genesis GP LLC | 4 | 公开市场买入 | $1000.0 万 | 1683.9 万股 |
| 2021-10-14 | Carl L Gordon | 4 | 公开市场买入 | $1000.0 万 | 1683.9 万股 |
| 2021-10-14 | Rock Springs Capital LLC | 4 | 公开市场买入 | $400.0 万 | 68.7 万股 |
| 2021-10-08 | Kathy Yi | 4 | 获授予/取得 | — | — |
| 2021-10-08 | Carl L Gordon | 4 | 获授予/取得 | — | — |
| 2021-10-08 | Iain D. Dukes | 4 | 获授予/取得 | — | — |
历史档案为按 SEC 数据集批量收录的申报记录,未逐条生成中文解读;金额 / 净股数由申报字段派生。完整原文以 SEC EDGAR 为准。
说明:此处的「内部人交易 / 高管持股异动」指公司内部人依法向 SEC 提交的 Form 3/4/5 持股披露,是合法的公开申报,
与「内幕交易」(利用未公开重大信息牟利的违法行为)是两回事,请勿混淆。